PCRX Pacira Pharmaceuticals: Accounting Value per Share

Graphic logo of Pacira BioSciences (PCRX)

Pacira BioSciences (PCRX) is developing non-opioid anesthesia, where success is based on the clinical adoption of Exparel, insurance reimbursement levels, and patent protection. The current metric stands at 16.84. The business faces the risk of losing hospital contracts due to new formulations of generic alternatives. This daily price chart below demonstrates the price action of the asset, for which physician confidence remains high despite periodic intellectual property legal disputes.

Pacira Pharmaceuticals (PCRX): Share Book Value from 07/04/2022 to 10/27/2026
Manufactured products of Pacira BioSciences, Inc.

The relevance of non-opioid analgesics ensures a sustainable market position for Pacira BioSciences (PCRX). The dynamics of net assets per share reflect the real value of an investor's stake after deducting all liabilities. This indicator measures the internal capital strength of the business, excluding market noise. Amidst generic expansion, analyzing this metric allows for an assessment of capital preservation. The stability of this trend guarantees protection against unjustified speculative risks.

Competitors of Pacira BioSciences (PCRX)

Net Assets per Single Share Haleon Group (HLN)|Kenvue Health (KVUE) - Accounting Value of a Share|Accounting Value per Share Verona Pharma plc|MENS (jyongbio.com) - Equity per Share|Net Assets per Single Share Ligand LGND|Share Book Value Amneal Pharmaceuticals, Inc.|Perrigo Company (PRGO) - Book Value per Share|Accounting Value of a Share Alvotech Biopharmaceuticals (ALVO)|Book Value per Share LQDA (Liquidia Corporation)|glpg.com - Book Value per Share|Net Assets per Single Share ANI Pharmaceuticals, Inc. (ANIP)|MNKD: Accounting Value of a Share|AMPH (Amphastar) - Net Assets per Single Share|ARS Corp (SPRY) - Accounting Value per Share|TBPH (Theravance Biopharma) - Book Value per Share|Book Value per Share aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Accounting Value per Share|Accounting Value of a Share TECX (tectonictx.com)|TNXP: Net Assets per Single Share|SXTC - Net Asset Value per Share|Accounting Value per Share Eupraxia Pharma EPRX|BHST - Book Price of a Share|Book Value per Share eXoZymes EXOZ|Oramed Pharmaceuticals Inc. (ORMP) - Accounting Value of a Share|Book Value per Share ENTX (Entera Bio Ltd)|Net Asset Value per Share HYFT|ABVC BioPharma (ABVC) - Net Assets per Single Share|Accounting Value of a Share CPIX (cumberlandpharma.com)|Quantum BioPharma (QNTM) - Net Assets per Single Share|Share Book Value FibroGen Inc FGEN|Telomir Pharma - Book Value per Share|RANI - Book Value per Share|SNYR (synergychc.com) - Book Value per Share|Rallybio (RLYB) - Accounting Value per Share|LEXX: Book Value per Share|Net Assets per Share PULM|Pheton Holdings Ltd (PTHL) - Net Assets per Single Share|Accounting Value of a Share aptorumgroup.com (APM)|Book Value per Share LYRA (Lyra Therapeutics, Inc.)|IBO - Book Value per Share|Accounting Value per Share TNF Pharma (TNFA)|YCBD - Accounting Value of a Share|PainReform Limited (PRFX) - Book Value per Share|Altamira Therapeutics Ltd. (CYTO) - Net Assets per Single Share|LIPO: Book Value per Share|Net Assets per Share OPTN|Pieris Pharmaceuticals, Inc. - Net Assets per Single Share|Net Asset Value per Share PROC (Procaps Group)|Net Assets per Single Share PTPI|Net Assets per Share Qilian International Corp QLI|SLRN: Book Value per Share|TFFP - Accounting Value per Share